1. Home
  2. NOTE vs CTXR Comparison

NOTE vs CTXR Comparison

Compare NOTE & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiscalNote Holdings Inc.

NOTE

FiscalNote Holdings Inc.

HOLD

Current Price

$0.77

Market Cap

15.9M

Sector

Technology

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.76

Market Cap

16.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOTE
CTXR
Founded
2013
2007
Country
United States
United States
Employees
439
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9M
16.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
NOTE
CTXR
Price
$0.77
$0.76
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$37.50
$6.00
AVG Volume (30 Days)
313.6K
636.8K
Earning Date
03-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.60
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$0.63
52 Week High
$5.59
$2.38

Technical Indicators

Market Signals
Indicator
NOTE
CTXR
Relative Strength Index (RSI) 30.92 45.08
Support Level $0.56 $0.70
Resistance Level $0.85 $0.99
Average True Range (ATR) 0.08 0.10
MACD -0.01 -0.01
Stochastic Oscillator 13.20 13.32

Price Performance

Historical Comparison
NOTE
CTXR

About NOTE FiscalNote Holdings Inc.

FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: